Pharmacological evidence for putative CCK(1) receptor heterogeneity in human colon smooth muscle.
1. The pharmacology of the cholecystokinin CCK(1) receptors endogenously expressed in human gallbladder and human ascending colon smooth muscle tissue was compared using radioligand binding assays. 2. Saturation analysis of the interaction between the radiolabelled, selective CCK(1)-receptor antagonist, [(3)H]-L-364,718, and enriched gastrointestinal tissue membranes suggested the presence of multiple binding sites in human colon but not human gallbladder. 3. Competition studies, using a range of structurally diverse, CCK-receptor selective ligands provided further evidence for CCK(1) receptor heterogeneity in human colon tissue (n(H) values significantly less than unity for SR27897=0.77+/-0.07, 2-NAP=0.73+/-0.03, YM220=0.70+/-0.09 and PD-134,308=0.83+/-0.01). Moreover, the competition data for SR27897, 2-NAP and YM220 were consistent with the interaction of these compounds at two binding sites. In contrast, in the human gallbladder assay, a single binding site model provided a good fit of the competition curve data obtained with all the CCK receptor selective compounds. 4. The data obtained are consistent with the presence of a single CCK(1) receptor binding site in the gallbladder but not in the colon. A two-site analysis of the colon data, indicated that one of the two sites was indistinguishable from that characterized in the gallbladder. The molecular basis of the apparent receptor heterogeneity in the colon remains to be established.
Morton
M F
MF
Academic Department of Surgery, GKT Schools of Medicine and Dentistry, King's College, London. mmorton1@prius.jnj.com
Harper
E A
EA
Tavares
I A
IA
Shankley
N P
NP
D001224:Aspartic Acid / Q000031:analogs & derivatives* / Q000494:pharmacology; D001665:Binding Sites; D001667:Binding, Competitive; D003106:Colon / Q000378:metabolism*; D020109:Devazepide / Q000494:pharmacology; D003975:Diazepam / Q000494:pharmacology; D005704:Gallbladder / Q000378:metabolism; D006801:Humans; D007210:Indoleacetic Acids / Q000494:pharmacology; D007700:Kinetics; D008566:Membranes; D008954:Models, Biological; D009130:Muscle, Smooth / Q000378:metabolism*; D009282:Naphthalenesulfonates / Q000494:pharmacology; D009924:Organ Culture Techniques; D009928:Organ Specificity; D011480:Protease Inhibitors / Q000494:pharmacology; D011869:Radioligand Assay; D043886:Receptor, Cholecystokinin A; D011949:Receptors, Cholecystokinin / Q000378:metabolism*; D013844:Thiazoles / Q000494:pharmacology; D013997:Time Factors
D007210:Indoleacetic Acids; D009282:Naphthalenesulfonates; D011480:Protease Inhibitors; D043886:Receptor, Cholecystokinin A; D011949:Receptors, Cholecystokinin; D013844:Thiazoles; C080460:SR 27897; C080661:N-(2-naphthalenesulfonyl)aspartyl-(2-phenethyl)amide; D001224:Aspartic Acid; D020109:Devazepide; D003975:Diazepam